>
Compass Therapeutics, Inc. logo

CMPX - Compass Therapeutics, Inc. Share Price

n/a 0.0  0.0%

Last Trade -

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 6927
Bullish
Bearish
Unlock CMPX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2021, CompassTherapeutics, Inc. revenues was not reported. Net lossincreased 16% to $7.4M. Higher net loss reflects Researchand developme increase of 31% to $4.6M (expense),Stock-based Compensation in SGA increase from $166K to$809K (expense), Stock-based Compensation in R&D increaseof 72% to $139K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CMPX Revenue Unlock CMPX Revenue

Net Income

CMPX Net Income Unlock CMPX Revenue

Normalised EPS

CMPX Normalised EPS Unlock CMPX Revenue

PE Ratio Range

CMPX PE Ratio Range Unlock CMPX Revenue

Dividend Yield Range

CMPX Dividend Yield Range Unlock CMPX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CMPX EPS Forecasts Unlock CMPX Revenue
Profile Summary

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is developing antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. Its immuno-oncology product candidates include a clinical-stage monoclonal antibody and a portfolio of bispecific antibodies. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. It is in Phase I clinical trial. It is also developing a portfolio of bispecific antibody product candidates, which are in preclinical development. It has also developed a transgenic mouse that produces antibodies with the differentiated property that they all share a human common light chain. It also provides CTX-8371, which is a bispecific antibody that simultaneously targets both PD-1 and PD-L1. CTX-8573 is its bispecific product candidate in this natural killer p30 (NKp30) innate cell engager class.

Directors
Last Annual December 31st, 2020
Last Interim March 31st, 2021
No. of Shareholders: 220
No. of Employees: 31
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Capital Market
Shares in Issue 51,313,454
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CMPX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CMPX
Upcoming Events for CMPX
Frequently Asked Questions for Compass Therapeutics, Inc.
What is the Compass Therapeutics, Inc. share price?

As of , shares in Compass Therapeutics, Inc. are trading at n/a, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Compass Therapeutics, Inc. share price performed this year?

Shares in Compass Therapeutics, Inc. are currently trading at n/a and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Compass Therapeutics, Inc. price has moved by % over the past year.

What are the analyst and broker recommendations for Compass Therapeutics, Inc.?

There are no analysts currently covering Compass Therapeutics, Inc..

When will Compass Therapeutics, Inc. next release its financial results?

Compass Therapeutics, Inc. is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Compass Therapeutics, Inc. dividend yield?

Compass Therapeutics, Inc. does not currently pay a dividend.

Does Compass Therapeutics, Inc. pay a dividend?

Compass Therapeutics, Inc. does not currently pay a dividend.

When does Compass Therapeutics, Inc. next pay dividends?

Compass Therapeutics, Inc. does not currently pay a dividend.

How do I buy Compass Therapeutics, Inc. shares?

To buy shares in Compass Therapeutics, Inc. you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Compass Therapeutics, Inc.?

Shares in Compass Therapeutics, Inc. are currently trading at n/a, giving the company a market capitalisation of £n/a.

Where are Compass Therapeutics, Inc. shares listed? Where are Compass Therapeutics, Inc. shares listed?

Here are the trading details for Compass Therapeutics, Inc.:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: CMPX
What kind of share is Compass Therapeutics, Inc.?

We were not able to load our ranking data for Compass Therapeutics, Inc.

Is there a Compass Therapeutics, Inc. share price forecast 2021?

We were not able to load any forecast data for Compass Therapeutics, Inc..

How can I tell whether the Compass Therapeutics, Inc. share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Compass Therapeutics, Inc.. Over the past six months, the relative strength of its shares against the market has been %. At the current price of n/a, shares in Compass Therapeutics, Inc. are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Compass Therapeutics, Inc. PE Ratio?

We were not able to find PE ratio data for Compass Therapeutics, Inc..

Who are the key directors of Compass Therapeutics, Inc.?

We were unable to find the directors for Compass Therapeutics, Inc..

Who are the major shareholders of Compass Therapeutics, Inc.?

Here are the top five shareholders of Compass Therapeutics, Inc. based on the size of their shareholding:

Similar to CMPX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.